Premium
Caveolin‐3 and sarcoglycans in the vacuolar myopathies and centronuclear myopathy
Author(s) -
Inose Masaru,
Higuchi Itsuro,
Nakagawa Masanori,
Kashio Nobuyuki,
Osame Mitsuhiro
Publication year - 1999
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/(sici)1097-4598(199908)22:8<1080::aid-mus12>3.0.co;2-t
Subject(s) - myopathy , dystrophin , pathology , lysosomal storage disease , caveolin 3 , glycogen storage disease , biology , muscular dystrophy , cancer research , microbiology and biotechnology , chemistry , medicine , genetics , disease , signal transduction , caveolae
Expression of dystrophin, β‐spectrin, merosin, and α‐ and β‐sarcoglycans on the vacuolar membranes in some types of vacuolar myopathies has previously been reported. We studied expression of caveolin‐3; α‐, β‐, γ‐, and δ‐sarcoglycans; dystrophin; and merosin on the vacuolar membranes in various vacuolar myopathies. Caveolin‐3 and dystrophin were expressed on the vacuolar membranes in lysosomal glycogen storage disease with normal acid maltase, hypokalemic myopathy, and centronuclear myopathy. Sarcoglycans and merosin were expressed only on the vacuolar membrane in lysosomal glycogen storage disease with normal acid maltase. Immunostain of caveolin‐3 and sarcoglycans is therefore useful for differential diagnosis of vacuolar myopathies. © 1999 John Wiley & Sons, Inc. Muscle Nerve 22: 1080–1086, 1999